FDA Raising Approval Bar For NSAID/PPI Combos; Endpoints Under Review

Regulatory briefings don't always just affect a single product; they can also be convened to discuss the regulatory parameters for a entire product class. One such briefing will be held in early 2009 to discuss the clinical trial design of NSAID/PPI combination products. Pozen is just one sponsor that will be affected by the outcome.

FDA is considering changes to the approval process for NSAID and proton pump inhibitor combination products that may result in the agency prohibiting the use of endoscopic gastric ulcer reduction to support a gastroprotective marketing claim.

That decision would raise the approval bar for a category of drugs that has recently become popular with certain companies:...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet